Study the effect of FGFR2 and FGFR4 gene variants on the response to cyclophosphamide doxorubicin-docetaxel based chemotherapy in locally advanced breast cancer patients

Abdelkarem, Omneya Ahmed Ibrahim; Hussein, Amr; Farouk, Ayman; Elsheredy, Heba; Abdel Aziz, Mai Mamdouh Sayed; Omer, Sahar Mohamed

doi:10.21608/jcbr.2024.294488.1357

Study the effect of FGFR2 and FGFR4 gene variants on the response to cyclophosphamide doxorubicin-docetaxel based chemotherapy in locally advanced breast cancer patients

Document Type : Original Article

Authors

¹ Department of Chemical Pathology, Medical Research Institute, Alexandria University

² Department of Clinical Oncology, Cancer Management and Research -Medical Research Institute – Alexandria University

³ Department of Experimental and Clinical Surgery – Medical Research Institute – Alexandria University

⁴ Assistant professor of clinical oncology. Department of Cancer Management and Research, Medical Research Institute, Alexandria University, Alexandria, Egypt

⁵ Department of Pathology- Medical Research Institute– Alexandria University

⁶ Department of of Chemical Pathology -Medical Research Institute – Alexandria University

10.21608/jcbr.2024.294488.1357

Abstract

Background: Breast cancer has significantly increased in Arab populations, accounting for 13-30% of the newly diagnosed women malignancies. Neoadjuvant chemotherapy, including regimens based on cyclophosphamide, doxorubicin, and docetaxel, is effective for early-stage operable and locally advanced cancer.However, chemoresistance remains a major challenge. Therefore, we aimed to study FGFR2 (rs2981578) and FGFR4 (rs1966265) gene variants in predicting chemotherapy response in patients with locally advanced breast cancer.

Methods: This cross-sectional study involved 30 females with biopsy confirmed locally advanced primary breast cancer. Patients received neoadjuvant anthracyclin-cyclophosphamide-docetaxel-based regimens. Core biopsies were taken for histopathological diagnosis, and immunohistochemistry for HER2, PR, and ER was performed. Genotyping of FGFR2 and FGFR4 SNPs was performed using the TaqMan SNP genotyping assay. The RECIST criteria was used for assessment of treatment response.

Results: 66.7% of patients responded to chemotherapy, while 33.3% did not. Premenopausal patients showed a significantly higher response rate compared to menopausal patients (FEp=0.024). The distribution of FGFR2 and FGFR4 genotypes did not show significant difference between responders and non-responders. (FEp=1.000).

Conclusion: The G and A alleles of FGFR2 and FGFR4 variants were not associated with chemotherapy response in this study. Further research with larger cohorts is needed to validate our study results and identify other variants that would guide tailored management.

Keywords